scPharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 136
- Market Cap
- $257.6M
- Introduction
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Pharmacokinetics and Pharmacodynamics of Subcutaneous vs Intravenous Furosemide in Healthy Volunteers
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06167707
- Locations
- 🇺🇸
Elixia EPCT, LLC, Tampa, Florida, United States
Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study
- First Posted Date
- 2020-10-20
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04593823
- Locations
- 🇺🇸
Cone Health Medical Group, Greensboro, North Carolina, United States
🇺🇸Cardiology Consultants, Pensacola, Florida, United States
🇺🇸First Coast Cardiovascular Institute, Jacksonville, Florida, United States
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04161482
- Locations
- 🇺🇸
Aventiv Clinical Research, Columbus, Ohio, United States
Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03458325
- Locations
- 🇺🇸
Tampa General Hospital, Tampa, Florida, United States
🇺🇸Olive View - UCLA Medical Center, Sylmar, California, United States
🇺🇸Unity Point Health, Des Moines, Iowa, United States
Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02804282
Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02804035
Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02561442
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02350725
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2015-01-01
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- scPharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT02329834
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States